查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1997198

切片檢查引導系統市場：2026-2032年全球市場預測（依影像技術、切片檢查類型、引導系統、應用和最終用戶分類）

Biopsy Guidance System Market by Imaging Technology, Biopsy Type, Guidance System, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，切片檢查引導系統市場價值將達到 16.6 億美元，到 2026 年將成長至 17.9 億美元，到 2032 年將達到 27.8 億美元，複合年成長率為 7.62%。

主要市場統計數據
基準年 2025 16.6億美元
預計年份：2026年 17.9億美元
預測年份 2032 27.8億美元
複合年成長率 (%) 7.62%

對切片檢查引導市場進行全面展望，為相關人員提出臨床、技術、監管和營運要求框架。

在臨床需求和技術成熟度的雙重驅動下，切片檢查引導生態系統正經歷快速創新期。臨床醫師在追求更高診斷準確率的同時，力求最大限度地減少患者的不適感和手術相關風險，這使得先進的影像技術和引導平台的重要性日益凸顯。同時，醫療設備製造商和解決方案供應商正致力於整合、互通性和工作流程最佳化，以縮短手術時間並提高可重複性。這些因素正在重塑醫院、門診和診斷機構的採購標準。

機器人技術、多模態成像和軟體智慧的創新融合如何重新定義切片檢查引導程序的準確性和臨床價值。

隨著機器人技術、先進影像技術和軟體智慧的融合，切片檢查引導領域正經歷變革，其操作精度和臨床可靠性也隨之提升。機器人輔助技術正從概念驗證階段走向常規工作流程，即使在解剖結構複雜的病例中，也能實現可重複的操作路徑和高度精確的目標定位。同時，電腦斷層掃描（CT）和磁振造影（MRI）等影像技術不斷提高軟組織對比度和空間解析度，超音波憑藉先進的2D、3D和多普勒功能而日益多樣化，從而拓展了其在臨床應用中的適用範圍。

評估近期美國關稅變化對指導體系中的採購、供應鏈韌性和產品架構的營運和策略影響。

美國近期關稅政策的變化進一步增加了切片檢查引導系統跨境採購和供應鏈規劃的複雜性。關稅調整影響範圍廣泛，涵蓋從影像處理電子元件到精密機械組件的各個方面，導致最終成本發生變化，並促使跨國供應商重新評估籌資策略。為此，許多供應商正在探索近岸外包方案、實現供應商多元化，並調整庫存策略以應對成本的快速波動。這些營運措施旨在維持利潤率，同時確保向高優先臨床客戶供應產品。

深入了解將影像方式、臨床應用、終端使用者環境、切片檢查技術和引導平台連接起來的細分市場，從而形成可操作的商業化路徑。

關鍵細分趨勢凸顯了臨床需求與技術差異化的交匯點，為有針對性的投資和商業化策略提供了指南。基於影像技術，市場涵蓋電腦斷層掃描 (CT)、磁振造影(MRI)、立體定位系統、超音波和X光設備，其中超音波進一步細分為2D超音波、3D超音波和多普勒超音波。每種成像方式在組織對比度、可及性和手術應用方面都具有獨特的優勢，從而影響設備的整合優先順序。基於應用領域，臨床重點領域涵蓋乳房、腎臟、肝臟、肺部、前列腺和甲狀腺手術，每種應用都有其獨特的影像、穿刺和切片檢查處理要求，這些要求會影響產品設計和培訓需求。

影響部署、夥伴關係和商業化策略的美洲、歐洲、中東、非洲和亞太地區的區域趨勢和營運流程。

區域趨勢影響技術的採用率、報銷框架和夥伴關係生態系統，了解這些細微差別對於制定有效的市場進入和擴大策略至關重要。在美洲，需求模式受到不同的支付方環境和臨床創新中心的影響，這些因素推動了先進導航平台的早期應用。採購決策通常受臨床證據和醫院系統優先事項的驅動，但門診中心越來越傾向於尋求經濟高效、高容量的解決方案。在歐洲、中東和非洲，不同的監管環境和基礎設施成熟度導致了不同的技術採用曲線。集中式的三級醫療機構是先進技術的中心，而經濟高效、可攜的設備則更受偏遠和資源匱乏地區的青睞。

那些優先考慮臨床證據、互通生態系統、模組化產品策略以及為買家提供全面生命週期支援的公司的競爭優勢。

切片檢查引導領域的競爭格局主要圍繞著那些成功將硬體可靠性、軟體智慧和卓越服務整合為一個完整價值提案的公司。主要企業透過持續投資於臨床證據、法規遵循和互通性來脫穎而出，從而促進與醫院資訊系統和影像檔案庫的整合。模組化產品生態系統——使醫療機構能夠從手動引導過渡到機器人輔助引導併升級影像模組——正受到那些優先考慮未來適應性和總體擁有成本的買家的青睞。

領導企業可採取的策略重點，以協調產品開發、證據產生、供應鏈韌性和商業性差異化服務模式。

產業領導企業應優先推進一系列舉措，將市場資訊轉化為永續的商業性優勢和臨床應用。首先，投資於能夠使產品開發與特定治療方式的性能要求和終端用戶實際工作流程相契合、減少操作差異並支持臨床醫生快速掌握相關技術的解決方案。其次，針對乳癌、肝癌、肺癌、攝護腺癌、腎臟癌和甲狀腺癌等關鍵適應症，建立強而有力的臨床證據項目，以展現比較優勢並支持有利的採購決策。第三，透過供應商多元化、評估近岸外包方案以及維持策略性庫存來增強供應鏈韌性，從而降低關稅和物流風險。

我們高度透明、以臨床醫生為中心的調查方法，結合與主要相關人員的對話、監管檢驗和情境分析，提供了切實可行的見解。

本研究結合了對臨床醫生、採購負責人和行業高管的訪談，以及對監管指南、臨床文獻和產品規格的廣泛審查，以確保獲得以臨床醫生為中心的可靠見解。資料收集強調跨職能觀點，以捕捉臨床工作流程、培訓需求和採購決策標準。分析方法將質性主題分析與產品特性和服務方案的結構化比較評估結合。這種方法有意優先考慮三角驗證，以協調不同相關人員的觀點，並為商業化和臨床部署提供可操作的見解。

整合臨床、技術和商業性需求，為切片檢查引導系統的廣泛應用和市場主導制定路徑。

總之，切片檢查引導領域正從漸進式改進邁向一體化創新階段，影像技術、機器人輔助和智慧軟體的進步正在融合，重新定義該手術的標準。臨床上對更高精度和更輕患者負擔的需求推動了技術的普及，而採購決策也越來越依賴臨床價值、互通性和服務連續性方面的證據。定價和供應鏈趨勢進一步增加了策略複雜性，迫使製造商和採購商優先考慮韌性和靈活性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：切片檢查引導系統市場的應用

  • 電腦斷層掃描
  • 磁振造影
  • 本土化
  • 超音波
    • 2D超音波
    • 3D超音波
    • 多普勒超音波
  • X光

第9章：依切片檢查類型分類的切片檢查引導系統市場

  • 核心針穿刺切片
    • 彈簧型
    • 吸力輔助型
  • 細針穿刺切片檢查

第10章：切片檢查引導系統市場指南（依系統分類）

  • 手動的
  • 機器人輔助

第11章：切片檢查引導系統市場：按應用領域分類

  • 胸部
  • 腎
  • 肝
  • 肺
  • 攝護腺
  • 甲狀腺

第12章：切片檢查引導系統市場：依最終用戶分類

  • 門診手術中心
  • 診斷影像中心
  • 醫院
    • 私立醫院
    • 公立醫院
  • 門診部

第13章：切片檢查引導系統市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：切片檢查引導系統市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：切片檢查引導系統市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國切片檢查引導系統市場

第17章：中國切片檢查引導系統市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Argon Medical Devices, Inc.
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • Boston Scientific Corporation
  • Canon Medical Systems Corporation
  • Cardinal Health, Inc.
  • Cook Medical, Inc.
  • Fujifilm Holdings Corporation
  • GE HealthCare Technologies Inc.
  • Hologic, Inc.
  • Koninklijke Philips NV
  • Medtronic plc
  • Olympus Corporation
  • Siemens Healthineers AG
  • Stryker Corporation
Product Code: MRR-C271879142B5

The Biopsy Guidance System Market was valued at USD 1.66 billion in 2025 and is projected to grow to USD 1.79 billion in 2026, with a CAGR of 7.62%, reaching USD 2.78 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.66 billion
Estimated Year [2026] USD 1.79 billion
Forecast Year [2032] USD 2.78 billion
CAGR (%) 7.62%

A definitive orientation to the biopsy guidance landscape that frames clinical drivers, technology enablers, regulatory pressures, and operational imperatives for stakeholders

The biopsy guidance ecosystem has entered a period of accelerated innovation driven by converging clinical imperatives and technology maturation. Clinicians seek higher diagnostic accuracy while minimizing patient discomfort and procedural risk, which has elevated the importance of advanced imaging modalities and guidance platforms. Simultaneously, device manufacturers and solution providers are focusing on integration, interoperability, and workflow efficiencies that reduce procedure time and enhance reproducibility. These forces are reshaping procurement criteria across hospitals, ambulatory centers, and diagnostic facilities.

Against this backdrop, stakeholders must navigate a complex interplay of clinical adoption pathways, regulatory expectations, and reimbursement dynamics. Evidence generation that demonstrates comparative clinical value increasingly influences adoption decisions, and payers are scrutinizing procedure outcomes and cost-effectiveness. As a result, product development roadmaps prioritize ease of use, reduced procedural variability, and compatibility with existing imaging infrastructure. This introduction frames the broader context for subsequent analysis by highlighting the clinical drivers, technology enablers, and operational priorities that are defining the current phase of market evolution.

How converging innovations in robotics, multimodal imaging, and software intelligence are redefining procedural precision and clinical value in biopsy guidance

The landscape for biopsy guidance is experiencing transformative shifts as robotics, imaging refinement, and software intelligence converge to elevate procedural precision and clinical confidence. Robotic assistance is moving beyond proof of concept toward integration in routine workflows, enabling reproducible trajectories and enhanced targeting in anatomically challenging cases. Concurrently, imaging technologies such as computed tomography and magnetic resonance imaging are delivering finer soft tissue contrast and spatial resolution, while ultrasound platforms are diversifying into advanced two dimensional, three dimensional, and Doppler capabilities that expand point-of-care applicability.

Moreover, the rise of real-time navigation systems and image fusion is smoothing the path for multimodal approaches that combine the strengths of each imaging modality. Software-driven decision support, including lesion characterization and trajectory planning, is becoming an expected component of comprehensive solutions. Taken together, these shifts are recalibrating value propositions: purchasers increasingly reward systems that reduce repeat procedures, shorten learning curves, and integrate with electronic medical records. As adoption accelerates, suppliers who prioritize validated clinical outcomes and interoperable ecosystems will be best positioned to capture sustained preference across varied clinical settings.

Assessing the operational and strategic consequences of recent United States tariff shifts on procurement, supply chain resilience, and product architecture for guidance systems

Recent tariff developments in the United States have introduced increased complexity into cross-border procurement and supply chain planning for biopsy guidance systems. Tariff adjustments affect components ranging from imaging electronics to precision mechanical assemblies, altering landed costs and prompting multinational vendors to reassess sourcing strategies. In response, many suppliers are evaluating nearshoring options, diversifying supplier bases, and adjusting inventory policies to buffer against sudden cost fluctuations. These operational moves aim to preserve margin while maintaining product availability for high-priority clinical customers.

Beyond direct cost implications, tariff-driven shifts can influence product architecture and aftersales economics. Manufacturers may redesign modules to rely on domestically sourced subcomponents or alter assembly footprints to mitigate exposure. Such redesign efforts have downstream effects on regulatory documentation and validation timelines, necessitating proactive change management. From a buyer perspective, procurement officers need to account for longer lead times and potential requalification activities when switching suppliers. Overall, tariffs are accelerating strategic supply chain resilience planning and making commercial agility a core competency for stakeholders across the value chain.

Segmentation insights that map imaging modalities, clinical applications, end-user settings, biopsy techniques, and guidance platforms into actionable commercialization pathways

Key segmentation dynamics reveal where clinical demand and technological differentiation intersect, offering guidance for targeted investment and commercialization strategies. Based on imaging technology, the market spans computed tomography, magnetic resonance imaging, stereotactic systems, ultrasound, and X ray equipment, with ultrasound further differentiated into two dimensional ultrasound, three dimensional ultrasound, and Doppler ultrasound; each modality carries distinct strengths for tissue contrast, accessibility, and procedural context, shaping device integration priorities. Based on application, clinical focus areas encompass breast, kidney, liver, lung, prostate, and thyroid procedures, and each application imposes unique imaging, needle access, and biopsy handling requirements that influence product design and training needs.

End-user segmentation identifies ambulatory surgical centers, diagnostic imaging centers, hospitals, and outpatient clinics as primary care settings, with hospitals further split into private and public institutions; these distinctions matter because procurement cycles, capital availability, and clinical governance vary substantially across settings. Based on biopsy type, practices differentiate between core needle biopsy and fine needle aspiration, while core needle approaches subdivide into spring loaded and vacuum assisted mechanisms; the choice among these reflects tradeoffs between tissue yield, procedural invasiveness, and pathology processing workflows. Finally, guidance system preferences fall across manual and robotic assisted platforms, and adoption trajectories depend on perceived gains in accuracy, workflow disruption, and clinician proficiency. Collectively, these segmentation lenses highlight opportunities for product tailoring, differentiated clinical evidence generation, and customized service models that address the specific needs of each modality, application, end user, and procedural technique.

Regional dynamics and operational pathways across the Americas, Europe Middle East and Africa, and Asia Pacific that influence adoption, partnerships, and commercialization strategies

Regional dynamics shape adoption speed, reimbursement frameworks, and partnership ecosystems, and understanding these nuances is essential for effective market entry and scale strategies. In the Americas, demand patterns are influenced by heterogeneous payer landscapes and concentrated centers of clinical innovation that drive early adoption of advanced guidance platforms; procurement decisions are often shaped by clinical evidence and hospital system priorities, while ambulatory centers increasingly seek cost-effective, high-throughput solutions. In Europe, Middle East & Africa, regulatory diversity and variable infrastructure maturity lead to differentiated adoption curves where centralized tertiary hospitals frequently act as hubs for sophisticated technologies, while remote and resource-constrained settings prioritize cost-effective, portable modalities.

Across Asia-Pacific, a mix of rapidly modernizing healthcare systems and large patient volumes creates both scale opportunities and the need for localized commercialization strategies; demand often favors adaptable solutions that align with diverse clinical workflows and varying levels of imaging infrastructure. Regional talent pools, local manufacturing incentives, and distribution partnerships further influence how companies deploy training, service models, and aftermarket support. By aligning product value propositions with regional clinical imperatives and procurement realities, stakeholders can optimize market entry sequencing and partnership selection to maximize clinical impact and commercial uptake.

Competitive company dynamics that reward clinical evidence, interoperable ecosystems, modular product strategies, and comprehensive lifecycle support for buyers

Competitive dynamics within the biopsy guidance arena center on firms that successfully blend hardware reliability, software intelligence, and service excellence into a coherent value proposition. Leading companies differentiate through sustained investment in clinical evidence, regulatory stewardship, and interoperability that eases integration with hospital information systems and imaging archives. Product ecosystems that offer modularity-allowing facilities to scale from manual to robotic assisted guidance or to upgrade imaging modules-tend to resonate with purchasers who prioritize future-proofing and total cost of ownership.

Additionally, companies that provide comprehensive training, remote support, and predictive maintenance capabilities can reduce procedural variability and enhance customer retention. Strategic partnerships between device makers, software vendors, and clinical centers generate real-world evidence and foster user communities that accelerate best-practice dissemination. New entrants face high expectations around clinical validation and service continuity, while incumbents must guard against commoditization by continuously enhancing user experience and demonstrating measurable outcomes. Hence, competitive advantage increasingly derives from a combination of clinical credibility, integration capability, and aftersales service depth.

Actionable strategic priorities for leaders to align product development, evidence generation, supply chain resilience, and commercially differentiated service models

Industry leaders should pursue a prioritized set of actions that translate market intelligence into sustained commercial advantage and clinical adoption. First, align product development with modality-specific performance requirements and end-user workflow realities, investing in solutions that reduce procedural variability and support rapid clinician proficiency. Second, build robust clinical evidence programs across key applications such as breast, liver, lung, prostate, kidney, and thyroid to validate comparative benefits and support favorable procurement decisions. Third, strengthen supply chain resilience by diversifying suppliers, evaluating nearshoring options, and maintaining strategic inventories to mitigate tariff and logistics risks.

In parallel, cultivate interoperable software platforms that facilitate image fusion, trajectory planning, and seamless integration with electronic health records to lower adoption barriers. Develop tailored commercial models that address the distinct needs of hospitals, ambulatory surgical centers, diagnostic imaging centers, and outpatient clinics, and offer flexible financing or bundled service agreements to ease capital constraints. Finally, invest in training, remote support, and predictive maintenance to reduce downtime and enhance clinician confidence. Executed coherently, these actions will improve clinical outcomes, accelerate adoption, and strengthen long-term partnerships with health systems and diagnostic providers.

A transparent and clinician centered research methodology combining primary stakeholder engagement, regulatory validation, and scenario analysis to underpin practical insights

This research synthesizes primary interviews with clinicians, procurement professionals, and industry executives alongside an extensive review of regulatory guidance, clinical literature, and product specifications to ensure robust, clinician-centric insights. Data collection emphasized cross-functional perspectives to capture clinical workflows, training requirements, and procurement decision criteria, and analytic methods integrated qualitative thematic analysis with structured comparative assessments of product capabilities and service offerings. The approach intentionally prioritized triangulation to reconcile divergent stakeholder perspectives and to surface pragmatic implications for commercialization and clinical adoption.

Quality assurance measures included validation of technical claims against regulatory filings and peer-reviewed clinical studies, as well as iterative review cycles with domain experts to refine interpretations. Where applicable, sensitivity testing was applied to supply chain and operational scenarios to assess resilience under different tariff and logistics conditions. The methodology is designed to be transparent and reproducible, providing stakeholders with confidence in the findings and enabling targeted follow-up analyses to address specific clinical or commercial questions.

Synthesis of clinical, technological, and commercial imperatives that define the pathway to wider adoption and leadership in biopsy guidance systems

In conclusion, the biopsy guidance field is transitioning from incremental improvements toward a phase of integrative innovation where imaging evolution, robotic assistance, and smart software converge to redefine procedural standards. Clinical demand for higher accuracy and reduced patient burden is catalyzing adoption, while procurement choices are increasingly shaped by evidence of clinical value, interoperability, and service continuity. Tariff and supply chain dynamics add another layer of strategic complexity, prompting manufacturers and purchasers to prioritize resilience and agility.

For stakeholders, the path forward involves aligning technology development with specific application needs, investing in rigorous clinical validation, and delivering tailored commercial and service models that reflect the realities of diverse end users and regions. Companies that successfully marry clinical credibility with operational reliability and flexible deployment models will lead adoption and create durable competitive positions. The industry is poised for impactful advances, and timely strategic choices will determine who captures leadership as technologies move from specialized settings into mainstream clinical practice.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biopsy Guidance System Market, by Imaging Technology

  • 8.1. Computed Tomography
  • 8.2. Magnetic Resonance Imaging
  • 8.3. Stereotactic
  • 8.4. Ultrasound
    • 8.4.1. 2D Ultrasound
    • 8.4.2. 3D Ultrasound
    • 8.4.3. Doppler Ultrasound
  • 8.5. X Ray

9. Biopsy Guidance System Market, by Biopsy Type

  • 9.1. Core Needle Biopsy
    • 9.1.1. Spring Loaded
    • 9.1.2. Vacuum Assisted
  • 9.2. Fine Needle Aspiration

10. Biopsy Guidance System Market, by Guidance System

  • 10.1. Manual
  • 10.2. Robotic Assisted

11. Biopsy Guidance System Market, by Application

  • 11.1. Breast
  • 11.2. Kidney
  • 11.3. Liver
  • 11.4. Lung
  • 11.5. Prostate
  • 11.6. Thyroid

12. Biopsy Guidance System Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Diagnostic Imaging Centers
  • 12.3. Hospitals
    • 12.3.1. Private Hospitals
    • 12.3.2. Public Hospitals
  • 12.4. Outpatient Clinics

13. Biopsy Guidance System Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Biopsy Guidance System Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Biopsy Guidance System Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Biopsy Guidance System Market

17. China Biopsy Guidance System Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Argon Medical Devices, Inc.
  • 18.6. B. Braun Melsungen AG
  • 18.7. Becton, Dickinson and Company
  • 18.8. Boston Scientific Corporation
  • 18.9. Canon Medical Systems Corporation
  • 18.10. Cardinal Health, Inc.
  • 18.11. Cook Medical, Inc.
  • 18.12. Fujifilm Holdings Corporation
  • 18.13. GE HealthCare Technologies Inc.
  • 18.14. Hologic, Inc.
  • 18.15. Koninklijke Philips N.V.
  • 18.16. Medtronic plc
  • 18.17. Olympus Corporation
  • 18.18. Siemens Healthineers AG
  • 18.19. Stryker Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BIOPSY GUIDANCE SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BIOPSY GUIDANCE SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY STEREOTACTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY STEREOTACTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY STEREOTACTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY 2D ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY 2D ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY 2D ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY 3D ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY 3D ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY 3D ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY DOPPLER ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY DOPPLER ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY DOPPLER ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY X RAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY X RAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY X RAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY SPRING LOADED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY SPRING LOADED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY SPRING LOADED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY VACUUM ASSISTED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY VACUUM ASSISTED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY VACUUM ASSISTED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY MANUAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY MANUAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY MANUAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ROBOTIC ASSISTED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ROBOTIC ASSISTED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ROBOTIC ASSISTED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BREAST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BREAST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BREAST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY KIDNEY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY KIDNEY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY KIDNEY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY LIVER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY LIVER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY LIVER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY LUNG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY LUNG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY LUNG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PROSTATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PROSTATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PROSTATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY THYROID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY THYROID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY THYROID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 171. GCC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GCC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 173. GCC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 174. GCC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. GCC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 176. GCC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 177. GCC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. GCC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. GCC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 198. G7 BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. G7 BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 200. G7 BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 201. G7 BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. G7 BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 203. G7 BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 204. G7 BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 205. G7 BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. G7 BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 207. NATO BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. NATO BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. NATO BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 210. NATO BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. NATO BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 212. NATO BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 213. NATO BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 214. NATO BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. NATO BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES BIOPSY GUIDANCE SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA BIOPSY GUIDANCE SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)